Japan’s Clinical Trial Reset: Can the Country Become Faster Without Losing Trust?

Japan’s clinical trial system is being quietly rebuilt. On paper, it can sound like technical policy: Single IRB, multinational clinical trials, drug lag, drug loss, decentralized trials, PMDA consultation, English documentation, priority review pathways. But behind the acronyms is a more human story. Medicines available overseas do not always reach Japanese patients quickly. Researchers can produce high-quality data, but procedures can be heavy. Hospitals are trusted, yet Japan can enter global development too late. Patients wait while the system tries to be careful.

The question in 2026 is not simply whether Japan can make trials faster. It is whether Japan can become faster without losing trust. Can it join global development earlier without weakening patient protection? Can it use AI, remote monitoring and digital consent while preserving data quality and ethical responsibility? Can it reduce drug lag and drug loss without forgetting why Japan tightened clinical research rules in the first place?

Japan.co.jp is treating this as a national innovation story because clinical trials are not just hospital paperwork. They are patient access, industrial policy, regional healthcare, scientific credibility and medical security. Japan has one of the world’s most advanced healthcare systems, a long-lived population, high-quality medical records and skilled clinicians. But in global drug development, being high-quality is not enough. Countries are chosen for speed, predictability, trial start-up capacity, patient recruitment and regulatory clarity. Japan is trying to fix the friction.

The 2026 issue: from drug lag to drug loss

For years, Japan spoke about “drug lag.” A medicine would be approved overseas, then reach Japan later. For patients, this was never an abstract regulatory delay. In cancer, rare disease, neurological disease and pediatric medicine, months and years matter.

Recently, a more troubling phrase has gained force: “drug loss.” The problem is not only that some medicines arrive late. Some may never enter development in Japan at all. PMDA materials have highlighted products approved in Europe or the United States but not approved in Japan, including a large number that had not even started development in Japan. Venture-origin medicines, orphan drugs and pediatric medicines appear especially vulnerable.

That difference matters. Drug lag means Japan is standing at the back of the line. Drug loss means Japan may not be in the line. If Japan is not included in early multinational development, later Japan-only studies become expensive and slow. If Japan’s pricing and trial environment look unattractive, overseas biotech companies may simply skip the market. Japanese patients then disappear from the first map of global medical innovation.

Why Japan was seen as high-quality but slow

Japan has real strengths. Its physicians and medical institutions are trusted. Records are careful. Patient follow-up is strong. Regulators are scientifically capable. Japanese clinical data are often respected.

But quality and speed are not the same thing. From the perspective of global sponsors, Japan has often looked expensive, complex and slow to start. Site contracting can take time. Ethics review can be fragmented. Documentation can be difficult for overseas teams. The role of Japanese Phase I data has not always been predictable. Large pharmaceutical companies can absorb this. Small biotech companies often cannot.

That is why Japan’s reform agenda is not merely scientific. Clinical trials are also logistics. They require clear contracts, aligned review processes, site budgets, patient recruitment, data systems and regulatory expectations. The goal is to reduce friction without weakening scientific standards.

The 2018 Clinical Trials Act: a heavy door built to protect trust

Any serious account of Japan’s clinical trial reset must begin with the Clinical Trials Act, enforced in April 2018. It followed concerns over inappropriate clinical studies, industry funding and conflict-of-interest transparency. The Act created stricter rules for specified clinical trials, including certified review board review, conflict-of-interest management and study-plan submission.

The purpose was necessary: to protect trust. Patients participate in research only when they believe investigators, hospitals, companies and regulators are acting honestly. Without transparency, the entire research system suffers.

But systems built to protect trust can become heavy. Researchers have pointed to increased administrative burdens and changes in investigator-initiated trial activity after the Act. This is Japan’s dilemma. Rules introduced to restore confidence can slow the very research that patients need. The answer is not to abandon safeguards. It is to make safeguards smarter, faster and more standardized.

Single IRB: a small phrase with large consequences

One of the most important reform concepts is Single IRB review for multi-site trials. Historically, Japan has often relied on site-by-site ethical review. That reflects caution, but it also creates delay. The more hospitals in a trial, the more reviews, amendments and local processes accumulate.

The International Bar Association has described Japan’s historical use of Single IRB in multi-site trials as very low, citing an approximately 1.3% figure from a 2025 survey context. If Japan wants to join global trials earlier and more often, ethics review cannot remain a bottleneck.

Single IRB is not a shortcut around ethics. Done properly, it clarifies responsibility, reduces duplication, improves consistency and accelerates site activation. It still must respect local conditions and patient communication. But if every hospital must start from scratch, Japan will struggle to match global development timelines.

The Japanese Phase I question

Another historic barrier has been the question of Japanese Phase I studies. Requiring Japanese safety data can make sense. Body size, metabolism, dose response and tolerability can vary. Patient safety matters.

But a blanket expectation for a Japan-specific Phase I study can delay entry into multinational trials. By the time a global program is already designed, adding Japan can become expensive or impractical. This is especially serious for rare diseases and pediatric medicines, where patient numbers are limited and every delay hurts.

Recent regulatory thinking has moved toward a more flexible, case-by-case approach. The question becomes: Is an additional Japanese Phase I study truly necessary? Can foreign data explain safety and tolerability adequately? Would earlier Japanese participation in a multinational trial better serve patients? This is not abandoning caution. It is using caution scientifically.

The Third Health and Medical Strategy: clinical trials become national strategy

On February 18, 2025, Prime Minister Shigeru Ishiba convened the 49th meeting of the Headquarters for Healthcare and Medical Strategy Promotion. Japan’s Phase III Healthcare Policy covers the five-year period beginning in fiscal 2025. Science Japan described the policy as focused on practical application of novel therapies and expansion of the drug discovery ecosystem. DIA Global Forum has highlighted infectious diseases and clinical trial acceleration as new points of emphasis.

The important shift is that clinical trials are no longer merely medical paperwork. They are part of national competitiveness. A country that can run high-quality trials quickly can attract drug development, support healthcare startups, prepare for infectious disease emergencies and give patients earlier access to innovation.

The pandemic made this painfully clear. In an infectious disease emergency, the speed of trial design, patient enrollment, data collection and international sharing can be lifesaving. A system that is slow in ordinary times will not become fast in a crisis. Japan needs a clinical trial ecosystem that is fast before the emergency arrives.

Decentralized trials: can patients participate without carrying the burden?

Decentralized clinical trials, or DCTs, are another piece of the reset. eConsent, telemedicine, wearable devices, home measurement, local pharmacies and remote monitoring can reduce the burden of participation. For older patients, rare-disease patients, parents, workers and people living far from major hospitals, travel itself can be a barrier to research.

DCTs are not magic. Remote data integrity, device accuracy, privacy, emergency procedures, investigational drug handling, physician oversight and missing-data analysis are all serious issues. Clinical Leader has described Japan’s DCT adoption as slow but steady, noting that 2024 policy documents offered direction on remotely collected data while broader guidance and centralized review remain areas of work.

For Japan, DCT is more than a trend. It connects directly to aging, depopulation, regional medicine and disaster resilience. If only people who can travel repeatedly to Tokyo or Osaka can participate in clinical trials, research will not fully represent Japan. A system that lets regional patients participate safely is a matter of fairness.

What trust requires now

When people hear “faster clinical trials,” they may fear weaker regulation. That is not the right goal. Japan should aim for trials that are faster because waste is removed, not because safety is reduced. Standardized contracts, efficient review, digital systems, earlier consultation, common templates and fewer duplicate steps can all accelerate research while preserving protection.

Trust also requires patient and public involvement. Patients are not data sources; they are partners. Patient and public involvement can help determine which endpoints matter, how heavy trial visits feel, whether consent forms are understandable and whether a study design respects real life. A faster system that does not listen to patients will fail ethically even if it succeeds administratively.

AI must be handled the same way. AI may help with protocol design, patient matching and data quality checks. But AI does not erase responsibility. In medical research, someone must remain accountable. Speed and transparency are not enemies. Transparency is what makes speed acceptable.

Japan.co.jp view

If Japan’s clinical trial reset works, the benefits could be large. Patients may gain earlier access to new therapies. Physicians and researchers may join global development closer to the beginning. Japanese pharmaceutical, device and healthcare startups may have a better home base for validation before going global. Regional hospitals may gain new opportunities through digital and networked research.

But reform can also become cosmetic. If Japan adopts the language of Single IRB without fixing contracts, budgets and staffing, trials will not become faster. If DCT becomes a slogan without improving the patient experience, it will disappoint. If policymakers talk about drug lag but fail to address pricing, startup incentives and market attractiveness, global developers may still put Japan later.

Japan’s strength is trust. Japan’s weakness is that procedures built to protect trust can sometimes forget the purpose of trust. Patients do not want slow safety. They want fast, accurate, explainable safety.

The 2026 clinical trial reset may look technical, but it is one of Japan’s most important healthcare stories. It asks how an aging society can still be a science nation. For patients waiting for a new therapy, reform is not an abstract policy. It is a trial opening earlier, Japan entering a global program from the start, or a rural patient being able to participate without relocating. That is where the future of medicine begins.

Reader guide